The thrombin generation potential increases after feminizing gender-affirming hormone treatment, decreases after masculinizing gender-affirming hormone treatment, and is determined by the hormone treatment regimen
Journal of Thrombosis and Haemostasis · 2025-10 · 23 (10) · 3084-3097
DOI: 10.1016/j.jtha.2025.03.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025-10. Verfasst von Mette Bøgehave und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, Esbjerg Hospital, University Hospital of Southern Denmark, Esbjerg, Denmark; Unit for Thrombosis Research, Depar…. Hauptthemen laut MEDLINE: Thrombin, Estradiol, Testosterone, Cyproterone Acetate. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Syddansk Universitet, Region Syddanmark.
Abstract (Originalsprache)
BACKGROUND: The effects of gender-affirming hormone therapy (GAHT) on the overall coagulation potential are not clarified. The global thrombin generation (TG) assay addresses the combined effect of coagulation factors and inhibitors. OBJECTIVES: We aimed to investigate changes in TG after initiation of feminizing or masculinizing GAHT. METHODS: We included a cohort of 270 transgender women and 348 transgender men aged >17 years. The primary outcomes were TG variables (endogenous thrombin potential [ETP], peak TG, and TG lag time) measured at baseline and after 12 months of feminizing GAHT (3 groups of oral/transdermal estradiol and cyproterone acetate) or masculinizing GAHT (7 groups of intramuscular/transdermal testosterone). RESULTS: In transgender women, ETP and peak TG increased after oral and transdermal estradiol (P < .001), and the largest increase was after oral estradiol (ΔETP: 113 nmol/L × min, P = .011; Δpeak TG: 28 nmol/L, P = .009). In transgender men, ETP or peak TG decreased after 6 testosterone modalities (P < .05) except transdermal testosterone. The largest 12 months effect was seen in transgender men receiving gestagen at baseline compared with intramuscular testosterone (ΔETP: -199 nmol/L × min, P < .001; Δpeak TG: -38 nmol/L, P = .008) and transdermal testosterone (ΔETP: -216 nmol/L × min, P < .001; Δpeak TG: -40 nmol/L, P = .007). Lag time was prolonged for 6 testosterone modalities (P < .05), except in the subgroup receiving baseline gestagen, with no between-group differences. CONCLUSION: Feminizing and masculinizing GAHT for 12 months affected coagulation in opposite directions. Feminizing GAHT was procoagulant, whereas masculinizing GAHT was anticoagulant. Of note, transdermal feminizing GAHT had the least pronounced procoagulant effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry, Esbjerg Hospital, University Hospital of Southern Denmark, Esbjerg, Denmark; Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Den…
- Department of Endocrinology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Department of Endocrinology and Center for Sexology and Gender, Ghent University Hospital, Flanders, Ghent, Belgium.
- Department of Endocrinology and Metabolism, Center of Expertise on Gender Dysphoria, Amsterdam University Medical Centers, the Netherlands.
Förderung
- Syddansk Universitet
- Region Syddanmark
Zitieren
APA
Bøgehave, M., Glintborg, D., Christensen, L. L., T'Sjoen, G., Vervalcke, J., Wiepjes, C. M., den Heijer, M., Andersen, M. S., & Bladbjerg, E. M. (2025). The thrombin generation potential increases after feminizing gender-affirming hormone treatment, decreases after masculinizing gender-affirming hormone treatment, and is determined by the hormone treatment regimen. Journal of Thrombosis and Haemostasis, 23(10), 3084-3097. https://doi.org/10.1016/j.jtha.2025.03.006
Vancouver
Bøgehave M, Glintborg D, Christensen LL, T'Sjoen G, Vervalcke J, Wiepjes CM, et al. The thrombin generation potential increases after feminizing gender-affirming hormone treatment, decreases after masculinizing gender-affirming hormone treatment, and is determined by the hormone treatment regimen. Journal of Thrombosis and Haemostasis. 2025;23(10):3084-3097. doi:10.1016/j.jtha.2025.03.006
BibTeX
@article{Bgehave2025,
author = {Bøgehave, Mette and Glintborg, Dorte and Christensen, Louise Lehmann and T'Sjoen, Guy and Vervalcke, Jeroen and Wiepjes, Chantal Maria and den Heijer, Martin and Andersen, Marianne Skovsager and Bladbjerg, Else-Marie},
title = {The thrombin generation potential increases after feminizing gender-affirming hormone treatment, decreases after masculinizing gender-affirming hormone treatment, and is determined by the hormone treatment regimen},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
volume = {23},
number = {10},
pages = {3084--3097},
doi = {10.1016/j.jtha.2025.03.006}
}
EUVIMED